ArticleCancers2022

Primary Chemoradiotherapy Treatment (PCRT) for HER2+ and Triple Negative Breast Cancer Patients: A Feasible Combination.

Raquel Ciérvide et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.